Surgical Stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns

Objective: The purpose of this study was to evaluate the survival estimates of stage III endometrial cancer patients, and also to detect the prognostic factors and failure patterns.

Materials and methods: Sixty-eight surgical Stage III endometrial cancer patients treated at Hacettepe University Hospital were included. All patients underwent surgical staging procedures consisting of peritoneal cytology, infracolic omentectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy and complete pelvic-paraaortic lymphadenectomy. By surgical staging 26 (38%) patients had Stage IIIA and 42 (62%) patients had Stage IIIC disease. The mean resected lymph node number was 26 (median, 25; range, 15-58).

Results: The median age was 60 years (range, 38-77), and the median follow-up period was 62 months (range, 36-90 months). The 5-year disease free survival rate was 58% and the 5-year overall survival rate was 64%. These figures for Stage IIIA were 60% and 68%, respectively; and for Stage IIIC they were 57% and 62%, respectively. No significant survival difference was detected between Stage IIIA and IIIC (p = 0.60 for disease-free survival and p = 0.48 for overall survival). High grade and positive peritoneal cytology predicted poor survival in both univariate (p = 0.004 and p = 0.006, respectively) and multivariate (p = 0.05 and p = 0.04, respectively) analysis. Twenty-eight patients (41%) had recurrence with a median time of 23 months (range, 10-54 months). Nine patients (13%) had only local, 13 patients (19%) had only distant and six patients (9%) had both local and distant relapse.

Conclusion: Surgical staging is important in the management of Stage III endometrial cancer, and the main problem is still distant failure. In multivariate analysis high grade and positive peritoneal cytology predicted poor survival significantly.

Stage III endometrial cancer; Survival; Prognostic factors; Failure patterns

[1] Creasman W., Odicino F., Maisonneuve P.. Benedet J., Shepherd J., Sideri M.: "Carcinoma of the corpus uteri. Annual report on the results of treatment in gynecological cancer". J. Epidemiol. Biostat., 1998, 3, 35.

[2] Aalders J. G., Abeler V., Kolstad P.: "Clinical (stage III) as compared to subclinical intrapelvic tumor spread in endometrial carcinoma: a clinical and histopathologic study of 175 patients". Gynecol. Oneal., 1984, 17, 64.

[3] Mackillop W. J., Pringle J. F.: "Stage III endometrial carcinoma" Cancer, 1985, 56, 2519.

[4] Greven K. M.,L anciano R. M.,C orn B.,C ase D., Randall M.E .: "Pathologic stage III endometrial carcinoma". Cancer, 1993, 71, 3697.

[5] Schorge J. O.,M olpus K. L.,G oodman A.,N ikrui N.,F uller A. F.: "The effect of postsurgical therapy on stage III endometrial carcinoma". Gynecol. Oneal., 1996, 63, 34.

[6] Burke T. W., Gershenson D. M.、Morris M., Stringer C. A., Levenback C., Totolero-Luna G., Baker V. V.: "Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma". Gynecol. Oneal., 1994, 55, 47.

[7] Aoki Y., Kase H., Watanabe M., Sato T., Kurata H., Tanaka K.: "Stage III endometrial cancer: Analysis of prognostic factors and failure patterns after adjuvant chemotherapy". Gynecol. Oneal., 2001, 83 (1), 1.

[8] Onda T., Yoshikawa H., Mizutani K., Mishima M., Yokota H., Nagano H., et al.: "Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy". Br. J. Cancer, 1997, 75 (12), 1836.

[9] Nelson G., Randall M., Sutton G., Moore D., Hurteau J., Look K.: "FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: Analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy". Gynecol. Oneal., 1999, 75, 211.

[10] McMeekin D. S., Lashbrook D., Gold M., Johnson G., Walker J L., Manuel R.: "Analysis of FIGO stage IIIC endometrial cancer patients". Gynecol. Oneal., 2001, 81, 273.

[11] Grigsby P. W., Perez C. A., Kuske R. R., Kao M. S., Galakatos A E.: "Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage Ill adenocarcinoma of the endometrium". Gynecol. Oneal., 1987, 27, 44.

[12] Hirahatake K.,H areyama H., Sakuragi N.,N ishiya M., Makinoda S., Fujimoto S.: "A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma". J. Surg. Oneal., 1997, 65 (2), 82.

[13] Morrow C. P., Bundy B. N., Kurman R. J., Creasman W. T., Heller P., Homesley H. D., Graham J.E.: "Relationship between surgical pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group Study". Gynecol. Oncol.,1991, 40, 55.

[14] Katz LA., Andrews S. J., Fanning J.: "Survival at'ler multimodality treatment for stage lllC endometrial cancer". Am. J. Obstet. Gynecol., 2001, 184, 1071.

[15] Rose P. G., Cha S. D., Tak W. K., Fitzgerald T., Reale F., Hunter R. E.: "Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma". Int. J. Radial. Oncol. Biol. Phys., 1992, 24, 229.

[16] Hicks M. L., Piver M. S., Puretz J. L., Hempling R. E., Baker T R., Mcauley M., Walsh D. L.: "Survival in patients with paraaortic lymph node metastases from endometrial adenocarcinoma clinically limited to the uterus". Int. J. Radiat. Oncol. Biol. Phys., 1993, 26, 607.

[17] Potish R. A.: "Abdominal radiotherapy for cancer of the utenne cervix and endometrium". Int. J. Radiat. Oneal. Biol. Phys., 1989, 16, 1453.